| Name | Eprosartan Mesylate |
| Description | Eprosartan Mesylate (SKF-108566J) is a competitive and reversible Angiotensin II Receptor Blocker. |
| In vitro | In a study involving brain and spinal cord injured rats, Eprosartan (0.3 mg/kg i.v.) was observed to induce a hypertensive response following spinal cord stimulation. |
| In vivo | Eprosartan effectively inhibits [125I]-Angiotensin II in human tissues (adrenal cortex, liver, cloned AT1 receptors) with an IC50 range of 1.4-3.9 nM and in rat tissues (mesenteric artery, adrenal cortex, glomeruli) with an IC50 range of 1.5-9.2 nM. In isolated perfused proximal tubules of rabbits, Eprosartan (100 nM) completely blocks the isosmotic fluid absorption induced by Angiotensin II. |
| Storage | Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | Ethanol : 4 mg/mL (7.68 mM), Sonication is recommended. 10% DMSO+40% PEG300+5% Tween 80+45% Saline : 4 mg/mL (7.68 mM), Sonication is recommended. DMSO : 104 mg/mL (199.76 mM), Sonication is recommended.
|
| Keywords | nonpeptid | Inhibitor | inhibit | Eprosartan Mesylate | Eprosartan | AT1 receptor | AT1 | antihypertensive | angiotensin-II | Angiotensin Receptor |
| Inhibitors Related | Losartan potassium | Tranilast | Enalapril Maleate | Telmisartan | Lisinopril dihydrate | Sacubitril/Valsartan | Benzyl benzoate | Irbesartan | Losartan | Ramipril | Diisononyl phthalate | Captopril |
| Related Compound Libraries | Highly Selective Inhibitor Library | FDA-Approved & Pharmacopeia Drug Library | Failed Clinical Trials Compound Library | Target-Focused Phenotypic Screening Library | Bioactive Compound Library | Membrane Protein-targeted Compound Library | Drug Repurposing Compound Library | Inhibitor Library | Anti-Cardiovascular Disease Compound Library | FDA-Approved Drug Library | Bioactive Compounds Library Max | Anti-Hypertension Compound Library |